Gentherm (THRM) Q2 2026 Earnings Call Transcript
Gentherm (THRM) reported Q2 2026 product revenue of $416 million, up 11% year over year, with 9.5% organic growth. Automotive climate and comfort revenue rose 14.1% (12.7% ex FX). Adjusted EBITDA was $48.8 million and non-GAAP EPS $0.75. The company raised 2026 guidance to $1.6 billion revenue and $185-$200 million adjusted EBITDA, and authorized $400 million in buybacks.
How this was made
The 30-second read
Why it matters
Traders can update valuation and positioning based on the raised 2026 revenue, EBITDA, and free cash flow guidance, plus the scale of the new share repurchase authorization and the stated financing package for the Modine transaction.
Market read
This is a guidance-and-capital-return earnings update with explicit 2026 ranges and transaction-related financing and integration milestones, making it directly tradable.
What to watch
The Modine closing timing (early Q4 2026) and warranty accrual dynamics may create execution risk; medical growth depends on device adoption and FDA clearance commercialization ramp.
Background
The transcript covers Gentherm’s Q2 2026 performance and forward-looking guidance, including expansion into medical and furniture markets and preparation for the Modine Performance Technologies combination.
Ticker impact
Gentherm reported Q2 results and raised 2026 guidance, including $1.6B revenue midpoint, $185M-$200M adjusted EBITDA, and $85M-$100M FCF.
Likely supports a near-term positive bias as guidance and capital return (new $400M buyback) reduce uncertainty, though Q3 margin headwinds may cap upside.
The article contains multiple concrete, decision-relevant datapoints: Q2 beats/trajectory, explicit 2026 guidance ranges, and a stated financing and integration timeline for the Modine transaction.
Market effects
Signals continued demand strength in automotive climate and comfort systems and expanding medical device exposure, which can influence read-across for thermal management and med-tech suppliers.
Highlights China growth from domestic OEM launches and higher take rates, supporting regional demand expectations for automotive components.
Modine integration and the 2030 revenue target can affect broader automotive supplier sentiment around diversification and light-vehicle exposure reduction.
Counterpoint
Despite guidance increases, management flags Q3 margin weakness from inflation recovery timing and inventory reductions, which could lead to a more cautious near-term multiple.
Key entities
- companyGentherm
Reported Q2 2026 results, raised 2026 guidance, authorized $400M buyback, and discussed Modine integration and medical expansion.
- companyModine Performance Technologies
Combination expected to close in early Q4 2026, with stated leverage and 2030 revenue targets for the combined company.
- companyInnovative Medical Equipment
Acquisition discussed as a catalyst for non-opioid pain management, including projected 2026 revenue contribution.
- productThermaZone
Therapy devices acquired via Innovative Medical Equipment, with projected 2026 full-year revenue contribution.
- productThermAffyx
FDA 510(k) cleared air-free patient warming solution with initial sales expected in Q3.